The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 19, 2023

Filed:

Mar. 24, 2022
Applicant:

Ipsen Biopharm Ltd., Wrexham, GB;

Inventors:

Sarah F. Blanchette, Lynnfield, MA (US);

Daryl C. Drummond, Lincoln, MA (US);

Jonathan Basil Fitzgerald, Arlington, MA (US);

Victor Moyo, Ringoes, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/436 (2006.01); A61K 31/4745 (2006.01); A61K 31/04 (2006.01); A61K 31/166 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 31/475 (2006.01); A61K 31/502 (2006.01); A61K 31/55 (2006.01); A61K 9/127 (2006.01); A61K 47/20 (2006.01); A61K 47/06 (2006.01); A61K 9/00 (2006.01); A61K 31/454 (2006.01); A61K 31/5025 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4745 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 31/04 (2013.01); A61K 31/166 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 31/436 (2013.01); A61K 31/454 (2013.01); A61K 31/475 (2013.01); A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K 47/20 (2013.01);
Abstract

Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.


Find Patent Forward Citations

Loading…